Literature DB >> 8137244

Camptothecins: from bench research to hospital wards.

M Potmesil1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1994        PMID： 8137244

Source DB:  PubMed          Journal:  Cancer Res        ISSN： 0008-5472            Impact factor:   12.701


× No keyword cloud information.
  55 in total

1.  Population pharmacokinetic and dynamic analysis of the topoisomerase I inhibitor lurtotecan in phase II studies.

Authors:  J H M Schellens; B Heinrich; M Lehnert; M E Gore; S B Kaye; P Dombernowsky; R Paridaens; A T van Oosterom; J Verweij; W J Loos; H Calvert; N Pavlidis; H Cortes-Funes; J Wanders; M Roelvink; C Sessa; K Selinger; P S Wissel; T Gamucci; A R Hanauske
Journal:  Invest New Drugs       Date:  2002-02       Impact factor: 3.850

2.  Multiple event activation of a generic prodrug trigger by antibody catalysis.

Authors:  D Shabat; C Rader; B List; R A Lerner; C F Barbas
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-08       Impact factor: 11.205

Review 3.  Camptothecin delivery methods.

Authors:  A Hatefi; B Amsden
Journal:  Pharm Res       Date:  2002-10       Impact factor: 4.200

4.  The mechanism of topoisomerase I poisoning by a camptothecin analog.

Authors:  Bart L Staker; Kathryn Hjerrild; Michael D Feese; Craig A Behnke; Alex B Burgin; Lance Stewart
Journal:  Proc Natl Acad Sci U S A       Date:  2002-11-08       Impact factor: 11.205

5.  Topoisomerase poisons activate the transcription factor NF-kappaB in ACH-2 and CEM cells.

Authors:  B Piret; J Piette
Journal:  Nucleic Acids Res       Date:  1996-11-01       Impact factor: 16.971

Review 6.  Clinical pharmacokinetics of irinotecan.

Authors:  G G Chabot
Journal:  Clin Pharmacokinet       Date:  1997-10       Impact factor: 6.447

Review 7.  Natural products as leads to anticancer drugs.

Authors:  M Gordaliza
Journal:  Clin Transl Oncol       Date:  2007-12       Impact factor: 3.405

8.  Pilot induction regimen incorporating pharmacokinetically guided topotecan for treatment of newly diagnosed high-risk neuroblastoma: a Children's Oncology Group study.

Authors:  Julie R Park; Jeffrey R Scott; Clinton F Stewart; Wendy B London; Arlene Naranjo; Victor M Santana; Peter J Shaw; Susan L Cohn; Katherine K Matthay
Journal:  J Clin Oncol       Date:  2011-10-17       Impact factor: 44.544

9.  Comparison of DC Bead-irinotecan and DC Bead-topotecan drug eluting beads for use in locoregional drug delivery to treat pancreatic cancer.

Authors:  Richard E J Forster; Sharon A Small; Yiqing Tang; Clare L Heaysman; Andrew W Lloyd; Wendy Macfarlane; Gary J Phillips; Milan D Antonijevic; Andrew L Lewis
Journal:  J Mater Sci Mater Med       Date:  2010-06-19       Impact factor: 3.896

Review 10.  Medicinal plants and cancer chemoprevention.

Authors:  Avni G Desai; Ghulam N Qazi; Ramesh K Ganju; Mahmoud El-Tamer; Jaswant Singh; Ajit K Saxena; Yashbir S Bedi; Subhash C Taneja; Hari K Bhat
Journal:  Curr Drug Metab       Date:  2008-09       Impact factor: 3.731
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.